Astellas Pharma Inc. · TSE:4503
Astellas Pharma — Q3 FY2017 Earnings Presentation
5 slides from Astellas Pharma's earnings presentation, January 2018
Slide 1: R&D Pipeline (As of Jan 2018) - Oncology (1/2)
R&D Pipeline (As of Jan 2018) Underlined items indicate changes from the previous announcement on Oct 31, 2017. Oncology (1/2) *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Gen
Slide 2: Oncology (2/2)
Oncology (2/2) Updates from the previous announcement (Oct. 2017): MDV3100 (enzalutamide): Applications for marketing approval for non-metastatic castration resistant prostate cancer in US and EU were submitted in Jan. 2018. Discontinued Phase 2 program for hepatocellular carcinoma because Phase 2 s
Slide 3: Urology and Nephrology
Urology and Nephrology *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Generic Name Form YM905 Muscarine M3 receptor antagonist Neurogenic detrusor overactivity in pediatric pati
Slide 4: Immunology and Neuroscience
Immunology and Neuroscience *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Generic Name Form FK506 Immunosuppressant Prevention of rejection after organ transplantation Filed (J
Slide 5: Others
Others *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Generic Name Form AMG 785 Anti-Sclerostin Osteoporosis for those at high risk of fracture Filed (Dec. 2016) / Japan Injecti